Biotech News

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

MannKind (MNKD)MannKindPartnership

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a

Related news

MNKDMannKind2026-10-10 00:00 EST

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

MNKDMannKind2026-07-24 10:30 EST

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

RYTMRhythm Pharmaceuticals2026-11-03 02:59 EST

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

SENSSenseonics2026-09-14 11:00 EST

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

ALGSAligos Therapeutics2026-07-06 20:05 EST

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

VANIVivani Medical2026-07-07 11:35 EST

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

VANIVivani Medical2026-08-06 12:00 EST

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

RYTMRhythm Pharmaceuticals2026-09-22 12:00 EST

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

SENSSenseonics2026-10-21 12:00 EST

Senseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern Time

SYBXSynlogic2026-07-29 11:00 EST

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

MannKind

Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...

Recent company news

Stock data

Close
3.95 USD
Market cap
1.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States